Published in J Neuropathol Exp Neurol on June 01, 2003
Innate immunity in the central nervous system. J Clin Invest (2012) 2.77
Multiple roles of chemokine CXCL12 in the central nervous system: a migration from immunology to neurobiology. Prog Neurobiol (2007) 2.18
HIV-associated neurocognitive disorder: pathogenesis and therapeutic opportunities. J Neuroimmune Pharmacol (2010) 1.87
Pathological expression of CXCL12 at the blood-brain barrier correlates with severity of multiple sclerosis. Am J Pathol (2008) 1.58
HIV-1-infected and/or immune activated macrophages regulate astrocyte SDF-1 production through IL-1beta. Glia (2006) 1.40
Human immunodeficiency virus type 1 gp120 induces apoptosis in human primary neurons through redox-regulated activation of neutral sphingomyelinase. J Neurosci (2004) 1.38
Neuronal chemokines: versatile messengers in central nervous system cell interaction. Mol Neurobiol (2007) 1.15
Regulation of neuronal P53 activity by CXCR 4. Mol Cell Neurosci (2005) 1.10
Calcium Signaling and Gliotransmission in Normal vs. Reactive Astrocytes. Front Pharmacol (2012) 1.06
Apoptotic and antiapoptotic effects of CXCR4: is it a matter of intrinsic efficacy? Implications for HIV neuropathogenesis. AIDS Res Hum Retroviruses (2004) 1.06
Differential expression of CXCL12 and CXCR4 during human fetal neural progenitor cell differentiation. J Neuroimmune Pharmacol (2007) 1.04
Chemokine CXCL12 in neurodegenerative diseases: an SOS signal for stem cell-based repair. Trends Neurosci (2012) 0.99
Differential effects of HIV infected macrophages on dorsal root ganglia neurons and axons. Exp Neurol (2007) 0.97
CXCL12-induced monocyte-endothelial interactions promote lymphocyte transmigration across an in vitro blood-brain barrier. Sci Transl Med (2012) 0.95
Brain dysfunction in the era of combination antiretroviral therapy: implications for the treatment of the aging population of HIV-infected individuals. Curr Opin Investig Drugs (2010) 0.91
SDF-1alpha/CXCL12 enhances GABA and glutamate synaptic activity at serotonin neurons in the rat dorsal raphe nucleus. Neuropharmacology (2009) 0.90
Monocytes mediate HIV neuropathogenesis: mechanisms that contribute to HIV associated neurocognitive disorders. Curr HIV Res (2014) 0.89
High-level C-X-C chemokine receptor type 4 expression correlates with brain-specific metastasis following complete resection of non-small cell lung cancer. Oncol Lett (2014) 0.88
Monocyte migration and LFA-1-mediated attachment to brain microvascular endothelia is regulated by SDF-1 alpha through Lyn kinase. J Immunol (2008) 0.83
Proteolytic processing of SDF-1α by matrix metalloproteinase-2 impairs CXCR4 signaling and reduces neural progenitor cell migration. Protein Cell (2012) 0.83
Protection of human cerebral neurons from neurodegenerative insults by gene delivery of soluble tumor necrosis factor p75 receptor. Exp Brain Res (2005) 0.82
Role of SDF1/CXCR4 interaction in experimental hemiplegic models with neural cell transplantation. Int J Mol Sci (2012) 0.81
Directed migration of human neural progenitor cells to interleukin-1β is promoted by chemokines stromal cell-derived factor-1 and monocyte chemotactic factor-1 in mouse brains. Transl Neurodegener (2012) 0.81
HIV-1, methamphetamine and astrocytes at neuroinflammatory Crossroads. Front Microbiol (2015) 0.80
HIV-1 endocytosis in astrocytes: a kiss of death or survival of the fittest? Neurosci Res (2014) 0.77
CXCL12-induced neurotoxicity critically depends on NMDA receptor-gated and L-type Ca(2+) channels upstream of p38 MAPK. J Neuroinflammation (2016) 0.76
Dopamine Increases CD14(+)CD16(+) Monocyte Transmigration across the Blood Brain Barrier: Implications for Substance Abuse and HIV Neuropathogenesis. J Neuroimmune Pharmacol (2017) 0.75
SDF-1/CXCR4 Signaling Maintains Stemness Signature in Mouse Neural Stem/Progenitor Cells. Stem Cells Int (2017) 0.75
Frontline Science: CXCR7 mediates CD14(+)CD16(+) monocyte transmigration across the blood brain barrier: a potential therapeutic target for NeuroAIDS. J Leukoc Biol (2017) 0.75
Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol (2006) 8.15
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol (2010) 5.03
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother (2013) 4.80
PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med (2010) 3.48
PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology (2013) 3.02
Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev (2012) 2.92
Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol (2008) 2.71
Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol (2010) 2.48
Atypical manifestations and poor outcome of herpes simplex encephalitis in the immunocompromised. Neurology (2012) 2.30
Prevalence of human immunodeficiency virus-associated cognitive impairment in a group of Hispanic women at risk for neurological impairment. J Neurovirol (2006) 2.27
Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS (2007) 2.09
Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS (2011) 2.04
Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner. PLoS One (2010) 1.95
"Wamepotea" (they have become lost): outcomes of HIV-positive and HIV-exposed children lost to follow-up from a large HIV treatment program in western Kenya. J Acquir Immune Defic Syndr (2011) 1.87
Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann Neurol (2004) 1.87
Synergistic increases in intracellular Ca2+, and the release of MCP-1, RANTES, and IL-6 by astrocytes treated with opiates and HIV-1 Tat. Glia (2005) 1.86
Adjusting mortality for loss to follow-up: analysis of five ART programmes in sub-Saharan Africa. PLoS One (2010) 1.84
Outcomes of antiretroviral therapy in children in Asia and Africa: a comparative analysis of the IeDEA pediatric multiregional collaboration. J Acquir Immune Defic Syndr (2013) 1.82
Mechanisms of the blood-brain barrier disruption in HIV-1 infection. Cell Mol Neurobiol (2005) 1.81
Eccentric target sign in cerebral toxoplasmosis: neuropathological correlate to the imaging feature. J Magn Reson Imaging (2010) 1.75
NMDA receptor activation by HIV-Tat protein is clade dependent. J Neurosci (2008) 1.74
Utility of molecular and serodiagnostic tools in cerebral toxoplasmosis with and without tuberculous meningitis in AIDS patients: A study from South India. Ann Indian Acad Neurol (2010) 1.72
HIV-tat induces formation of an LRP-PSD-95- NMDAR-nNOS complex that promotes apoptosis in neurons and astrocytes. Proc Natl Acad Sci U S A (2007) 1.71
Activated T-cells inhibit neurogenesis by releasing granzyme B: rescue by Kv1.3 blockers. J Neurosci (2010) 1.69
Role of Tat protein in HIV neuropathogenesis. Neurotox Res (2009) 1.60
Challenges to the diagnosis and management of HIV dementia. AIDS Read (2006) 1.55
CD4-independent infection of astrocytes by human immunodeficiency virus type 1: requirement for the human mannose receptor. J Virol (2004) 1.52
Cocaine-mediated enhancement of Tat toxicity in rat hippocampal cell cultures: the role of oxidative stress and D1 dopamine receptor. Neurotoxicology (2005) 1.51
HIV-1 Tat protein alters tight junction protein expression and distribution in cultured brain endothelial cells. J Neurosci Res (2003) 1.43
Morphine causes rapid increases in glial activation and neuronal injury in the striatum of inducible HIV-1 Tat transgenic mice. Glia (2008) 1.42
Induction of IL-17 and nonclassical T-cell activation by HIV-Tat protein. Proc Natl Acad Sci U S A (2013) 1.41
Neuronal apoptosis is mediated by CXCL10 overexpression in simian human immunodeficiency virus encephalitis. Am J Pathol (2004) 1.40
Regional patterns of brain metabolites in AIDS dementia complex. Neuroimage (2004) 1.40
Estrogen attenuates gp120- and tat1-72-induced oxidative stress and prevents loss of dopamine transporter function. Synapse (2006) 1.40
A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clin Cancer Res (2005) 1.39
Proton MRS and neuropsychological correlates in AIDS dementia complex: evidence of subcortical specificity. J Neuropsychiatry Clin Neurosci (2007) 1.39
TorsinA protein and neuropathology in early onset generalized dystonia with GAG deletion. Neurobiol Dis (2003) 1.39
Intracellular human immunodeficiency virus Tat expression in astrocytes promotes astrocyte survival but induces potent neurotoxicity at distant sites via axonal transport. J Biol Chem (2003) 1.38
Apoptotic death of striatal neurons induced by human immunodeficiency virus-1 Tat and gp120: Differential involvement of caspase-3 and endonuclease G. J Neurovirol (2004) 1.38
Synaptic transport of human immunodeficiency virus-Tat protein causes neurotoxicity and gliosis in rat brain. J Neurosci (2003) 1.35
HIV-1 protein Tat potentiation of methamphetamine-induced decreases in evoked overflow of dopamine in the striatum of the rat. Brain Res (2003) 1.34
A multi-center 1H MRS study of the AIDS dementia complex: validation and preliminary analysis. J Magn Reson Imaging (2003) 1.34
Signaling mechanisms of HIV-1 Tat-induced alterations of claudin-5 expression in brain endothelial cells. J Cereb Blood Flow Metab (2005) 1.33
HIV-Tat protein induces oxidative and inflammatory pathways in brain endothelium. J Neurochem (2003) 1.31
CXCL10-induced cell death in neurons: role of calcium dysregulation. Eur J Neurosci (2006) 1.31
HIV-1 neuropathogenesis: glial mechanisms revealed through substance abuse. J Neurochem (2006) 1.31
Quantification of accuracy and precision of multi-center DTI measurements: a diffusion phantom and human brain study. Neuroimage (2011) 1.30
HIV-1 Tat protein upregulates inflammatory mediators and induces monocyte invasion into the brain. Mol Cell Neurosci (2003) 1.29
Permeability of the blood-brain barrier to HIV-1 Tat. Exp Neurol (2005) 1.28
Neurological complications of immune reconstitution in HIV-infected populations. Ann N Y Acad Sci (2010) 1.28
Temporal relationships between HIV-1 Tat-induced neuronal degeneration, OX-42 immunoreactivity, reactive astrocytosis, and protein oxidation in the rat striatum. Brain Res (2003) 1.27
Neuroimaging correlates of HIV-associated BBB compromise. J Neuroimmunol (2004) 1.27
Immune reconstitution inflammatory syndrome and the central nervous system. Curr Opin Neurol (2011) 1.27
Progressive multifocal leukoencephalopathy in transplant recipients. Ann Neurol (2011) 1.26
Relative sensitivity of magnetic resonance spectroscopy and quantitative magnetic resonance imaging to cognitive function among nondemented individuals infected with HIV. J Int Neuropsychol Soc (2008) 1.26
Interactive comorbidity between opioid drug abuse and HIV-1 Tat: chronic exposure augments spine loss and sublethal dendritic pathology in striatal neurons. Am J Pathol (2010) 1.25
A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis. Brain (2008) 1.25
Neuropathology of HIV/AIDS with an overview of the Indian scene. Indian J Med Res (2005) 1.23
The HIV Dementia Scale: predictive power in mild dementia and HAART. J Neurol Sci (2007) 1.23
Novel markers of oxidative stress in actively progressive HIV dementia. J Neuroimmunol (2004) 1.21
HIV-1 Tat neurotoxicity in primary cultures of rat midbrain fetal neurons: changes in dopamine transporter binding and immunoreactivity. Neurosci Lett (2005) 1.21
Identification of active loci of a human endogenous retrovirus in neurons of patients with amyotrophic lateral sclerosis. Ann Neurol (2011) 1.21
Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression. Immunobiology (2009) 1.20
The clinical burden of tuberculosis among human immunodeficiency virus-infected children in Western Kenya and the impact of combination antiretroviral treatment. Pediatr Infect Dis J (2009) 1.19
Granzyme B mediates neurotoxicity through a G-protein-coupled receptor. FASEB J (2006) 1.19
betaA3/A1-crystallin in astroglial cells regulates retinal vascular remodeling during development. Mol Cell Neurosci (2007) 1.18
Viral RNA silencing suppressors (RSS): novel strategy of viruses to ablate the host RNA interference (RNAi) defense system. Virus Res (2010) 1.17
Perturbation of host nuclear membrane component RanBP2 impairs the nuclear import of human immunodeficiency virus -1 preintegration complex (DNA). PLoS One (2010) 1.17
A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes. J Neurovirol (2013) 1.16
Inflammatory changes and breakdown of microvascular integrity in early human immunodeficiency virus dementia. J Neurovirol (2004) 1.15
Human herpes 6 virus encephalitis complicating allogeneic hematopoietic stem cell transplantation. Neurology (2013) 1.15
Increasing incidence of ischemic stroke in patients with HIV infection. Neurology (2011) 1.14
Antifungal coating by biofunctionalized polyelectrolyte multilayered films. Biomaterials (2005) 1.13
Identification of two novel activities of the Wnt signaling regulator Dickkopf 3 and characterization of its expression in the mouse retina. BMC Cell Biol (2007) 1.13
The basement membrane microenvironment directs the normalization and survival of bioengineered human skin equivalents. Matrix Biol (2007) 1.13
JC virus antibody and viremia as predictors of progressive multifocal leukoencephalopathy in human immunodeficiency virus-1-infected individuals. Clin Infect Dis (2011) 1.13
Neurotoxic effects of the human immunodeficiency virus type-1 transcription factor Tat require function of a polyamine sensitive-site on the N-methyl-D-aspartate receptor. Brain Res (2002) 1.12
Immune reconstitution is not a prognostic factor in progressive multifocal leukoencephalopathy. J Neuroimmunol (2011) 1.12
Matrix metalloproteinase 1 interacts with neuronal integrins and stimulates dephosphorylation of Akt. J Biol Chem (2003) 1.11
Impact of opiate-HIV-1 interactions on neurotoxic signaling. J Neuroimmune Pharmacol (2006) 1.11
Editorial neuroAIDS review. AIDS (2011) 1.10
Eradication of HIV from the brain: reasons for pause. AIDS (2011) 1.10
Proinflammatory synergism of ethanol and HIV-1 Tat protein in brain tissue. Exp Neurol (2005) 1.10
Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch Neurol (2008) 1.10
Human immunodeficiency virus type 1 Tat and methamphetamine affect the release and activation of matrix-degrading proteinases. J Neurovirol (2004) 1.08
Depressive symptoms, quality of life, and neuropsychological performance in HIV/AIDS: the impact of gender and injection drug use. J Neurovirol (2005) 1.08
Associations of cigarette smoking with viral immune and cognitive function in human immunodeficiency virus-seropositive women. J Neurovirol (2007) 1.07
The human immunodeficiency virus type-1 transcription factor Tat produces elevations in intracellular Ca2+ that require function of an N-methyl-D-aspartate receptor polyamine-sensitive site. Brain Res (2004) 1.07
Re: Atypical manifestations and poor outcome of herpes simplex encephalitis in the immunocompromised. Neurology (2013) 1.07
Where does HIV hide? A focus on the central nervous system. Curr Opin HIV AIDS (2013) 1.07
Degradability of polysaccharides multilayer films in the oral environment: an in vitro and in vivo study. Biomacromolecules (2005) 1.06
Platelet decline: an avenue for investigation into the pathogenesis of human immunodeficiency virus -associated dementia. Arch Neurol (2007) 1.06
Increased vulnerability of ApoE4 neurons to HIV proteins and opiates: protection by diosgenin and L-deprenyl. Neurobiol Dis (2006) 1.06
Methamphetamine potentiates HIV-1 Tat protein-mediated activation of redox-sensitive pathways in discrete regions of the brain. Exp Neurol (2003) 1.06
NeuroAIDS in Africa. J Neurovirol (2010) 1.05